reports
- Laura Chico
- Thomas Yip
Biogen and Dayra Therapeutics Announce Research Collaboration to Disco...
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions Oral macrocyclic peptides have the potential to offer biologic-like efficacy and safety in a convenient oral formatCollaboration further advances Biogen’s immunology strategy by broadening its early-stage pipeline and incorporating an additional clinically validated modality into its expanding immunology capabilities CAMBRIDGE, Mass. and TORONTO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Inc. (Nasdaq: BIIB) and Dayra Therapeutics today announced...
- Laura Chico
- Thomas Yip
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
n this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
SHOO STEVEN MADDEN LTD.
NTRA NATERA
MMS MAXIMUS INC.
ISRG INTUITIVE SURGICAL INC.
HOO HERBALIFE NUTRITION LTD.
HIG HARTFORD FINANCIAL SERVICES GROUP INC.
CPSI COMPUTER PROGRAMS & SYSTEMS INC.
BIIB BIOGEN INC.
ADMA ADMA BIOLOGICS INC
D4V G. WILLI-FOOD INTERNATIONAL LTD.
LZB LAZBOY INCORPORATED
HOFT HOOKER FURNITURE CORP.
TNDM TANDEM DIABETES CARE
RCUS ARCUS BIOSCIENCES
CSTL CASTLE BIOSCIENCES
TXG 10X GENOMICS INC CLASS A
NRIX NURIX THERAPEUTICS
ADPT ADAPTIVE BIOTECHNOLOGIES
TYRA TYRA BIOSCIENCES INC
GFR GREENFIRE RESOURCES LTD
SOLV_w SOLVENTUM CORPORATION
PACS PACS GROUP INC
NUTX NUTEX HEALTH INC
BBNX BETA BIONICS
KLRS KALARIS THERAPEUTICS INC
CCHH CCH HOLDINGS LTD
FBRX FORTE BIOSCIENCES INC
- Emira Sagaama
- Rok Stibric
- Laura Chico
- Thomas Yip
- Emira Sagaama
- Rok Stibric
- Martial Descoutures
- Martial Descoutures
Biogen to Highlight New Lecanemab Data and Scientific Advances at the ...
Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference New lecanemab findings highlight the safety and potential benefits of subcutaneous administration for initiation dosing, the potential for additional long-term clinical benefits with continued treatment, and real-world experienceBiogen is committed to deepening scientific understanding of Alzheimer’s disease, including therapeutic delivery and disease progression CAMBRIDGE, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inc. (Nasdaq: BIIB) today announced upcoming scien...
Novartis announces plans to build flagship manufacturing hub in North ...
Novartis announces plans to build flagship manufacturing hub in North Carolina Expansion represents significant investment in North Carolina and is expected to create 700 new jobs in the state by end of 2030Enables manufacturing of medicines across company’s main therapeutic areas in one geographic locationMarks latest milestone in company’s previously announced $23 billion investment in US infrastructure East Hanover, November 19, 2025 – Novartis, a leading global innovative medicines company, today announced plans to expand its operations in North Carolina, creating a new flagship manufa...
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural...
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments – Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative to children with typical development – – Findings underscore the urgent need for new medicines that target the underlying genetic cause of Dravet syndrome to improve long-term outcomes...
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the...
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-naive participants and those transitioning from the currently approved 12mg dose regimen1Final European Commission decision expected in January 2026SMA is a rare, genetic, neuromuscular disease that affects individuals of all ages2 CAMBRIDGE, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BIIB) today announced the Committee for Medicinal Products for H...
- Wedbush Research
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
PTGX PROTAGONIST THERAPEUTICS
ANAB ANAPTYSBIO INC.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
ACET INC.
STTK ADICET BIO INC
TVTX SHATTUCK LABS
VRDN TRAVERE THERAPEUTICS INC
SANA VIRIDIAN THERAPEUTICS INC
PHVS SANA BIOTECHNOLOGY
DAWN PHARVARIS NV
STX DAY ONE BIOPHARMACEUTICALS INC
GFS SEAGATE TECHNOLOGY HLDGS PLC
EWTX GLOBALFOUNDRIES INC
NUVL EDGEWISE THERAPEUTICS INC
ARTV NUVALENT INC
SYRE ARTIVA BIOTHERAPEUTICS INC
RNAC SPYRE THERAPEUTICS INC.
CARTESIAN THERAPEUTICS INC
- Laura Chico
- Thomas Yip
Biogen Completes Acquisition of Alcyone Therapeutics
Biogen Completes Acquisition of Alcyone Therapeutics CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative CNS therapy delivery solutions, such as the ThecaFlex DRx™ drug delivery system. ThecaFlex DRx™ is an investigational implantable device designed to provide an alternative to repeat lumbar punctures in chronic intrathecal administration of medicines, which could ease both patient experience and accessibility for a broader population of people liv...
- Laura Chico
- Thomas Yip
- Wedbush Research
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
PEGA PEGASYSTEMS INC.
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
IMAX IMAX CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
BIIB BIOGEN INC.
AXTI AXT INC.
ARDX ARDELYX INC
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
ARGX ARGENX ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
SMCI SUPER MICRO COMPUTER
TVTX INC.
RZLT TRAVERE THERAPEUTICS INC
STX REZOLUTE
VERA SEAGATE TECHNOLOGY HLDGS PLC
GFS VERA THERAPEUTICS INC
ALCC GLOBALFOUNDRIES INC
DBD ALTC ACQUISITION CORP
MAZE DIEBOLD NIXDORF INCORPORATED
JBIO MAZE THERAPEUTICS INC
JADE BIOSCIENCES INC
- Laura Chico
- Thomas Yip
Novartis opens new radioligand therapy manufacturing facility in Calif...
Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan Carlsbad location is company’s third US-based radioligand therapy (RLT) manufacturing site New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and HawaiiFirst to have delivered at scale, Novartis fortifies leadership in RLT innovation and infrastructure with California facility, additional plans for Florida and Texas Basel, November 10, 2025 – Novartis, a leading global innovative m...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.